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Abstract 
Background: Current irritability is associated with greater retrospective and current bipolar disorder (BD) illness 
severity; less is known about prospective longitudinal implications of current irritability. We examined relationships 
between current irritability and depressive recurrence and recovery in BD.
Methods: Outpatients referred to the Stanford BD Clinic during 2000–2011 were assessed with the Systematic 
Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation at baseline, and with the Clinical 
Monitoring Form during follow-up during up to 2 years of naturalistic treatment. Prevalence and clinical correlates 
of any current irritability in depressed and recovered (euthymic ≥8 weeks) BD patients were assessed. Kaplan–Meier 
analyses (Log-Rank tests) assessed relationships between current irritability and longitudinal depressive severity, with 
Cox Proportional Hazard analyses assessing potential mediators.
Results: Recovered BD outpatients with vs. without current irritability had significantly higher rates of 13/19 (68.4 %) 
other baseline unfavorable illness characteristics/current mood symptoms and hastened depressive recurrence 
(Log-Rank p = 0.020), driven by lifetime history of anxiety disorder and prior year rapid cycling, and attenuated by his-
tory of psychosis. Depressed BD outpatients with vs. without current irritability had significantly higher rates of 7/19 
(36.8 %) other unfavorable illness characteristics/current mood symptoms and delayed depressive recovery (Log-Rank 
p = 0.034), NOT mediated by any assessed parameter.
Limitations: Limited generalizability beyond our predominately white, female, educated, insured American BD spe-
cialty clinic sample.
Conclusions: Current irritability was associated with hastened depressive recurrence and delayed depressive recov-
ery in BD. Treatment studies targeting irritability may yield strategies to mitigate increased longitudinal depressive 
burden.
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Background
Bipolar disorder (BD) is a chronic illness associated with 
high rates of recurrence and impaired functionality (Ket-
ter 2010; Solomon et  al. 1995). Up to one-half of BD 
patients have mood episode recurrence within 1 year of 
recovery (Solomon et  al. 1995), commonly with severe 
consequences, including higher rates of non-response, 
social morbidity, and impaired functioning (Berk et  al. 
2011; Lish et al. 1994; Rosa et al. 2012). Although mood 
elevation episodes define BD, bipolar depression is more 
pervasive (Judd et  al. 2002, 2003), and has been associ-
ated with functional impairment (Goldberg and Harrow 
2011; Gyulai et  al. 2008) and suicidality (Dilsaver et  al. 
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1997; Suttajit et al. 2013), with the latter present in almost 
four fifths of depressed patients (Dilsaver et  al. 1997). 
Notably, even subsyndromal depressive symptoms can 
undermine function (Altshuler et al. 2006; Goldberg and 
Harrow 2011). In addition, bipolar depression negatively 
impacts BD illness course; with illness severity worsening 
with recurrent episodes, independent of treatment (Maj 
et al. 1992).
Previous studies have demonstrated current irritability 
to be both highly prevalent and indicative of worse illness 
severity in acute bipolar depression. Irritability is a core 
symptom of depression in children and adolescents (but 
not in adults) (American Psychiatric Association 2013), 
and is present in up to three quarters of depressed BD 
patients (Winokur et  al. 1969). Current irritability has 
been associated with multiple unfavorable illness charac-
teristics in bipolar depression, including earlier onset age 
and higher rates of suicidal ideation, axis I comorbidity, 
atypical depressive features, and depressive mixed states 
(Balázs et  al. 2006; Benazzi and Akiskal 2005; Benazzi 
et  al. 2004). Additionally, current irritability appears 
closely related to current anxiety and lifetime history of 
anxiety disorder in BD (Yuen et al. 2016).
The negative longitudinal impact of current mood 
symptoms is well established (Maj et  al. 2003; Perlis 
et al. 2006). Residual affective symptoms (which may be 
related to irritability) in recovered patients predicted 
hastened episode recurrence (Perlis et  al. 2006). Also, 
among depressed bipolar I disorder patients, those with 
agitation (over half of whom had irritability) compared 
to those without agitation (only 15 % of whom had irrita-
bility) had significantly delayed depressive recovery (Maj 
et  al. 2003). However, the association between current 
irritability and bipolar course requires further examina-
tion. In this prospective study, we examined longitudinal 
relationships between current irritability and depressive 
recurrence and recovery in bipolar disorder patients.
Methods
Outpatients referred to the Stanford Bipolar Disorder 
Clinic from 2000 to 2011 were assessed using the System-
atic Treatment Enhancement Program for BD (STEP-BD) 
Affective Disorders Evaluation (Sachs et al. 2002, 2003), 
which included the structured clinical interview for the 
fourth edition of the diagnostic and statistical manual of 
mental disorders (SCID for DSM-IV) (First et  al. 1997) 
mood disorders module and the Clinical Global Impres-
sion for Bipolar Disorder-Overall Severity (CGI-BP-OS) 
score (Spearing et al. 1997). The Mini International Neu-
ropsychiatric Interview (MINI) (Sheehan et al. 1998) was 
also performed to confirm bipolar and comorbid psy-
chiatric disorder diagnoses. Patients were followed pro-
spectively for up to 2  years, while receiving naturalistic 
treatment with a monthly modal visit frequency. The 
Clinical Monitoring Form (CMF) (Sachs et al. 2002) was 
used to assess clinical status at each follow-up visit. The 
Stanford University Administrative Panel on Human 
Subjects approved the STEP-BD protocol, as well as the 
subsequent similar Assessment, Monitoring, and Cen-
tralized Database protocol specific to Stanford Univer-
sity. Both protocols conformed to the standards of the 
Helsinki Declaration of 1975, and all subjects provided 
verbal and written informed consent before participating 
in the study.
Current irritability was assessed based on patient recall 
of the number of days among the 10 days prior to enroll-
ment during which they experienced any irritability on 
the STEP-BD Affective Disorders Evaluation. For the 
primary analysis, we examined current irritability dichot-
omized according to the presence or absence of any irri-
tability. For secondary analyses, we examined current 
irritability dichotomized according to the presence or 
absence of irritability for at least four and at least seven of 
the prior 10 days.
Trained medical and research staff collected data on 
6 demographic parameters and 19 illness characteris-
tics/current mood symptoms. The demographic param-
eters assessed were: (A) age (in years), (B) gender, (C) 
race/ethnicity, (D) education, (E) marital status, and (F) 
employment status. The illness characteristics/current 
mood symptoms assessed were: (1) lifetime anxiety dis-
order; (2) lifetime alcohol/substance use disorder; (3) 
lifetime eating disorder; (4) lifetime personality disorder; 
(5) bipolar II disorder; (5A) lifetime psychosis (which is 
very commonly associated with Bipolar I disorder); (5B) 
lifetime prior psychiatric hospitalization (which is also 
very commonly associated with bipolar I disorder); (6) 
≥one first degree relative with mood disorder; (7) onset 
age (in years); (8) childhood (age <13  years) onset; (9) 
illness duration (in years); (10) Long illness duration 
(≥15 years); (11) episode accumulation (≥10 prior mood 
episodes); (12) lifetime suicide attempt; (13) rapid cycling 
in prior year; and (14) CGI-BP-OS; as well as current (i.e., 
any in the prior 10  days) (15) sadness; (16) anhedonia; 
(17) euphoria; (18) irritability; and (19) anxiety.
Statistical analyses were performed using Statisti-
cal Package for the Social Sciences (SPSS) Version 23.0 
software (IBM Corp.; Armonk, NY, USA) on an Apple 
MacBook Air computer (Apple Corporation, Cupertino, 
CA, USA). Prevalence and clinical correlates of current 
irritability were examined in currently recovered (i.e., 
euthymic ≥8  weeks) and currently depressed (i.e., with 
a current major depressive episode) patients. Analyti-
cal statistics included Fisher’s Exact test comparisons of 
categorical data and independent-sample t test compari-
sons of continuous variables. In addition, binary logistic 
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regression was used to adjust for potential confound-
ing variables. Primary longitudinal analyses consisted 
of Kaplan–Meier survival analyses (Log-Rank tests), 
which compared times to depressive recurrence and 
recovery in patients with and without current irritability. 
We used the standard approaches of censoring patients 
with mood elevation prior to depressive recurrence in 
assessing time to depressive recurrence, and censoring 
patients with depressive prior to mood elevation recur-
rence in assessing time to mood elevation recurrence 
(Perlis et  al. 2006). Secondary analyses included Cox 
proportional hazard analyses [hazard ratios (HRs) and 
95 % confidence intervals (CIs)] of depressive recurrence 
and recovery, as well as of potential mediators of statis-
tically significant longitudinal depressive illness severity 
findings. To select parameters for entry into mediator 
models, univariate Cox proportional hazard analyses 
were performed for all statistically significant clinical 
correlates of current irritability. Parameters with p < 0.05 
were entered into a forward stepwise procedure, and 
covariates were included in the model if p < 0.05. Addi-
tionally, Cox proportional hazard analyses with time-
dependent covariates were used to further characterize 
associations between current irritability and depressive 
recurrence and recovery. We used a two-tailed signifi-
cance threshold with p  <  0.05, with no correction for 
multiple comparisons.
Results
Table  1 includes demographics, illness characteristics, 
and current mood symptoms of currently recovered and 
currently depressed patients, stratified by the presence 
or absence of any current irritability. In our overall sam-
ple of 503 outpatients with bipolar I disorder or bipolar 
II disorder, 105 (20.9  %) were currently recovered and 
153 (30.4 %) were currently depressed. The prevalence of 
current irritability was nearly twice as high among cur-
rently depressed (68.6 %) vs. recovered (36.2 %, χ2 = 31.4, 
df = 1, p < 0.0001) patients.
Demographics and illness characteristics/current mood 
symptoms in recovered patients with vs. without current 
irritability
Among recovered patients, the presence compared to 
the absence of current irritability was significantly less 
common (36.2 vs. 63.8 % had and lacked current irritabil-
ity, respectively, binomial test p < 0.0001). Nevertheless, 
recovered patients with vs. without current irritability 
had significantly higher rates lifetime anxiety (60.5 vs. 
38.8 %, χ2 = 4.6, df = 1, p = 0.042) and alcohol/substance 
use (71.1 vs. 38.8 %, χ2 = 10.1, df = 1, p = 0.002) disor-
der, bipolar II disorder (57.9 vs. 28.4 %, χ2 = 8.9, df = 1, 
p = 0.004), having ≥one first degree relative with a mood 
disorder (63.2 vs. 37.3 %, χ2 = 6.5, df = 1, p = 0.015), epi-
sode accumulation (≥10 prior episodes, 66.7 vs. 42.4 %, 
χ2 = 5.0, df = 1, p = 0.031), lifetime suicide attempt (44.4 
vs. 16.7 %, χ2 = 9.2, df = 1, p = 0.004), prior year rapid 
cycling (18.9 vs. 4.8 %, χ2 = 5.1, df = 1, p = 0.037), cur-
rent sadness (31.6 vs. 11.9 %, χ2 = 6.1, df = 1, p = 0.020), 
anhedonia (23.7 vs. 9.0  %, χ2 =  4.3, df =  1, p =  0.047), 
euphoria (34.2 vs. 1.5 %, χ2 =  22.5, df =  1, p < 0.0001), 
irritability (by definition 100.0 vs. 0.0  %, χ2  =  105.0, 
df = 1, p < 0.0001), and anxiety (57.9 vs. 23.9 %, χ2 = 12.2, 
df = 1, p = 0.0007), as well as earlier onset age (17.0 ± 8.4 
vs. 20.8 ± 8.9, t = −2.2, df = 102, p = 0.034) and worse 
(higher) CGI-BP-OS (2.6  ±  0.6 vs. 1.9  ±  0.8, t  =  4.7, 
df =  103, p  <  0.001) (Table  1). Although current irrita-
bility was inversely associated with history of psychosis 
(31.6 vs. 55.2 %, χ2 = 5.5, df = 1, p = 0.025) and prior psy-
chiatric hospitalization (31.6 vs. 55.2 %, χ2 = 5.5, df = 1, 
p = 0.025), both of these relationships were mediated by 
the association of bipolar II subtype with current irrita-
bility. In contrast, no assessed demographic parameter 
and no other illness characteristic in Table 1 were signifi-
cantly associated with current irritability among recov-
ered patients.
Demographics and illness characteristics/current mood 
symptoms in depressed patients with vs. without current 
irritability
Among currently depressed patients, presence com-
pared to absence of current irritability was significantly 
more common (68.6 vs. 31.4  % had and lacked cur-
rent irritability, respectively, binomial test p  <  0.0001). 
Current irritability was significantly associated with 
higher rates of lifetime anxiety disorder (84.8 vs. 60.4 %, 
χ2  =  11.1, df  =  1, p  =  0.002), bipolar II disorder (69.5 
vs. 43.8  %, χ2  =  9.2, df  =  1, p  =  0.004), having ≥one 
first degree relative with a mood disorder (65.7 vs. 
45.8 %, χ2 =  5.4, df =  1, p =  0.022), episode accumula-
tion (≥10 prior mood episodes, 78.1 vs. 58.7 %, χ2 = 5.8, 
df = 1, p = 0.027), and current euphoria (34.3 vs. 14.6 %, 
χ2 = 6.3, df = 1, p = 0.012), irritability (by definition 100.0 
vs. 0.0 %, χ2 = 153.0, df = 1, p < 0.0001), and anxiety (86.7 
vs. 68.8 %, χ2 = 6.9, df = 1, p = 0.014), as well as earlier 
onset age (15.6 ± 6.3 vs. 20.5 ± 9.5, t = −3.8, df = 151, 
p  <  0.001) (Table  1). The inverse relationship between 
current irritability and prior psychiatric hospitalization 
(21.0 vs. 37.5 %, χ2 = 4.7, df = 1, p = 0.047) was mediated 
by the association of bipolar II subtype with current irri-
tability. In addition, although current irritability was sig-
nificantly associated with a lower rate of having a college 
degree (38.1 vs. 66.7 %, χ2 = 10.8, df = 1, p = 0.002), all 
significant findings in Table  1 remained so after adjust-
ing for education. In contrast, no other assessed demo-
graphic parameter and no other illness characteristic in 
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Table 1 were significantly associated with current irrita-
bility among depressed patients.
Current irritability in relationship to time to and frequency 
of depressive recurrence
Current irritability was significantly associated with 
hastened depressive recurrence (Log-Rank p  =  0.020) 
in 38 vs. 67 recovered patients with vs. without current 
irritability (Fig.  1). Current irritability was also signifi-
cantly associated with hastened depressive recurrence 
using Cox Proportional Hazard analysis (HR = 2.1; 95 % 
CI 1.1–4.2; p =  0.024). Hastened depressive recurrence 
among patients with current irritability was driven by 
lifetime anxiety disorder (HR  =  3.8; 95  % CI 1.6–9.1; 
p = 0.002) and prior year rapid cycling (HR = 2.6; 95 % 
CI 0.99–6.9; p  =  0.052), and attenuated by history of 
psychosis (HR  =  0.38; 95  % CI 0.17–0.88; p  =  0.023). 
The Kaplan–Meier estimated depressive recurrence 
rate was only non-significantly higher among patients 
with (58.9  %; 95  % CI 40.3–77.5  %) compared to 
Table 1 Demographics, illness characteristics, and current mood symptoms in recovered and depressed bipolar disorder 
outpatients with and without current irritability
CGI-BP-OS clinical global impression for bipolar disorder-overall severity, SD standard deviation
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 with vs.  Underline font indicates parameters with statistically significant relationships with current irritability. Italic 
font indicates parameters associated with bipolar I subtype. Missing data among recovered patients: 12.4 % for ≥10 prior episodes, 0.0–6.7 % for other parameters. 
Missing data among depressed patients: 7.2 % for ≥10 prior episodes, 0.0–1.3 % for other parameters
Currently recovered Currently depressed
Current irritability No current irritability Current irritability No current irritability
N (%) 38 (36.2)**** 67 (63.8) 105 (68.6)**** 48 (31.4)
Demographics
 A. Age (years, mean ± SD) 36.3 ± 14.0 35.9 ± 13.6 35.5 ± 13.2 37.8 ± 14.0
 B. Female (%) 60.5 52.2 65.7 52.1
 C. Caucasian (%) 69.4 80.3 87.6 85.4
 D. College degree (%) 64.9 61.5 38.1** 66.7
 E. Married (current, %) 42.1 33.3 38.1 35.4
 F. Full-time employment (current, %) 40.5 30.3 29.5 17.0
Comorbid disorders (lifetime, %)
 1. Anxiety 60.5* 38.8 84.8** 60.4
 2. Alcohol/Substance Use 71.1** 38.8 59.0 56.3
 3. Eating 10.5 9.0 21.9 12.5
 4. Personality 10.5 7.5 18.1 6.3
Other illness characteristics
 5. Bipolar II disorder (%) 57.9** 28.4 69.5** 43.8
 5A. Psychosis (lifetime, %) 31.6 55.2* 32.4 43.8
 5B. Psychiatric hospitalization (lifetime, %) 31.6 55.2* 21.0 37.5*
 6. ≥One 1° degree relative w mood disorder (%) 63.2* 37.3 65.7* 45.8
 7. Onset age (years, mean ± SD) 17.0 ± 8.4* 20.8 ± 8.9 15.6 ± 6.3*** 20.5 ± 9.5
 8. Childhood (age <13 years) onset (%) 21.6 9.0 26.7 14.6
 9. Illness duration (years, mean ± SD) 20.2 ± 16.1 15.8 ± 12.2 19.5 ± 13.8 17.0 ± 11.4
 10. Long illness duration (≥15 years, %) 50.0 46.8 52.9 54.2
 11. Episode accumulation (≥10, lifetime, %) 66.7* 42.4 78.1* 58.7
 12. Suicide attempt (lifetime, %) 44.4** 16.7 32.7 37.5
 13. Rapid cycling (prior year, %) 18.9* 4.8 31.1 25.0
 14. CGI-BP-OS (current, mean ± SD) 2.6 ± 0.6*** 1.9 ± 0.8 5.4 ± 0.8 5.3 ± 0.6
Current mood symptoms (any in prior 10 days, %)
 15. Sadness 31.6* 11.9 89.5 89.6
 16. Anhedonia 23.7* 9.0 95.2 93.8
 17. Euphoria 34.2**** 1.5 34.3* 14.6
 18. Irritability 100.0**** 0.0 100.0**** 0.0
 19. Anxiety 57.9*** 23.9 86.7* 68.8
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without (42.2 %; 95 % CI 25.7–58.7 %) current irritabil-
ity. Although recovered patients with compared to with-
out current irritability overall had hastened depressive 
recurrence, as suggested by visual inspection of Fig.  1, 
patients with current irritability had depressive recur-
rence significantly less often after compared to before 
day 180. In other words, current irritability’s association 
with hastened depressive recurrence was significant up 
to 180 days (HR = 5.3; 95 % CI 2.0–3.6; p = 0.001), but 
became non-significant after 180 days (HR = 0.50; 95 % 
CI 0.14–1.8; p = 0.29). This appeared to contribute to the 
black (with current irritability) curve flattening and con-
verging with the still declining gray (without current irri-
tability) curve after 180 days (Fig. 1).
In contrast, associations between current irritabil-
ity and times to mood elevation recurrence (Log-Rank 
p = 0.18, HR = 0.48; 95 % CI 0.16–1.4; p = 0.19, in 38 vs. 
67 recovered patients with vs. without current irritability, 
not illustrated) and any mood episode recurrence (Log-
Rank p = 0.30, HR = 1.3; 95 % CI 0.78–2.3; p = 0.30, in 
38 vs. 67 recovered patients with vs. without current irri-
tability, not illustrated) were non-significant.
Upon examining current irritability thresholded for 
having occurred on at least four of the prior 10  days 
and at least seven of the prior 10 days, the relationships 
between current irritability and times to depressive 
recurrence were non-significant.
Current irritability in relationship to time to and frequency 
of depressive recovery
Current irritability was significantly associated with 
delayed depressive recovery (Log-Rank p = 0.034) in 105 
vs. 48 depressed patients with vs. without current irri-
tability (Fig. 2). Current irritability was also significantly 
associated with delayed depressive recovery using Cox 
Proportional Hazard analysis (HR = 0.62; 95 % CI 0.39–
0.97; p = 0.034). No other assessed parameter mediated 
the relationship between current irritability and delayed 
depressive recovery. Median time to recovery was more 
than twice as long among patients with current irritability 
(412 days; 95 % CI 295.3–528.7) compared to those with-
out current irritability (184  days; 95  % CI 154.7–213.3). 
The Kaplan–Meier estimated 2-year overall depressive 
recovery rate was 83.0 %, and was very similar and only 
non-significantly lower among patients with (82.1  %; 
95 % CI 71.9–92.3 %) vs. without (85.1 %; 95 % CI 71.0–
99.2  %) current irritability. As expected, the Kaplan–
Meier estimated 1-year overall depressive recovery rate 
was lower, at only 57.2  %. Although depressed patients 
without compared to with current irritability overall took 
less than half as long to recover, as suggested by visual 
inspection of Fig.  2, patients without current irritability 
recovered significantly less often in the second compared 
to the first year. In other words, the relationship between 
current irritability and delayed depressive recovery was 
significant up to 360 days (HR = 0.47; 95 % CI 0.29–0.78; 
p  =  0.004), but became non-significant after 360  days 
(HR = 2.2; 95 % CI 0.53–9.8; p = 0.27). This appeared to 
contribute to the gray (without current irritability) curve 
flattening and converging with the still rising black (with 
current irritability) curve in the second year (Fig. 2).
In addition, current irritability was significantly related 
to delayed recovery from any mood episode (Log-Rank 
p = 0.029, HR = 0.63; 95 % CI 0.41–0.96; p = 0.031, in 
147 vs. 59 patients in a current mood episode with vs. 
without current irritability, not illustrated). However, the 
association between current irritability and time to mood 
elevation recovery (Log-Rank p = 0.35, HR = 0.57; 95 % 
CI 0.17–1.9; p  =  0.36, in 42 vs. 11 manic/hypomanic/
mixed patients with vs. without current irritability, not 
illustrated) was non-significant.
Current irritability dichotomized for having occurred 
on at least four and seven of the prior 10  days was not 
and was significantly associated with delayed recovery 
from depression, respectively.
Fig. 1 Current irritability associated with hastened depressive 
recurrence in bipolar disorder. Two-year survival analysis of time 
to depressive recurrence in recovered bipolar disorder patients 
indicated significantly hastened depressive recurrence in patients 
with (N = 38, black line on bottom) vs. without (N = 67, gray line on 
top) current irritability (Log-Rank p = 0.020). Current irritability was 
also significantly associated with hastened depressive recurrence 
using Cox Proportional Hazard analysis (HR = 2.1; 95 % CI 1.1–4.2; 
p = 0.024). History of anxiety disorder (HR = 3.8, p = 0.002) and prior 
year rapid cycling (HR = 2.6, p = 0.052) drove and history of psychosis 
(HR = 0.38, p = 0.023) attenuated hastened depressive recurrence in 
patients with vs. without current irritability
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Discussion
In this prospective study, we found that current irrita-
bility had statistically significant associations with both 
hastened depressive recurrence and delayed depressive 
recovery. Whereas the relationship between current irri-
tability and hastened depressive recurrence was driven by 
history of anxiety disorder and prior year rapid cycling, 
and attenuated by history of psychosis, that between 
current irritability and delayed depressive recovery 
was not significantly mediated by any other assessed 
parameter. The unfavorable relationship between cur-
rent irritability and illness severity may have been even 
more robust among currently recovered vs. currently 
depressed patients, considered not only at baseline (sig-
nificantly associated with 68.4 vs. 36.8 % unfavorable ill-
ness characteristics/current mood symptoms) but also 
possibly longitudinally (depressive recurrence hastened 
with p  =  0.020 vs. depressive recovery delayed with 
p = 0.034).
Our rates of depressive recurrence and recovery were 
comparable to those found in other studies. A review of 
naturalistic studies with 2–2.5  years of follow-up deter-
mined a mean depressive recurrence rate of 55.7  % 
(Vazquez et  al. 2015), as compared to 48.2  % within 
2 years in the current study. Moreover, a prior study by 
Otto et  al. reported that 58.4  % of patients recovered 
from bipolar depression within 1 year (Otto et al. 2006), 
while 57.2 and 83.0 % of our patients achieved recovery 
within one or 2 years, respectively.
The association between current irritability and has-
tened depressive recurrence suggests that irritability 
could have adverse longitudinal effects upon depressive 
recurrence similar to bipolar disorder residual mood 
symptoms considered in aggregate. Residual affective 
symptoms considered in aggregate not only predicted 
mood episode recurrence (Judd et  al. 2008; Keller et  al. 
1992; Perlis et  al. 2006), but also were associated with 
additional unfavorable illness characteristics, such as sui-
cidal behavior and Axis I comorbidity (MacQueen et al. 
2003; Parmentier et al. 2012). Furthermore, although irri-
tability has been more extensively studied in the context 
of mania, hypomania, and mixed depression (Balázs et al. 
2006; Benazzi 2007; Benazzi and Akiskal 2003b; Gold-
berg et al. 2009; Winokur and Tsuang 1975), the impact 
of irritability during euthymia is becoming increasingly 
apparent (Parmentier et  al. 2012). Our findings extend 
prior observations by suggesting that current irritabil-
ity is associated with hastened depressive recurrence. 
Indeed, irritability may be similar to residual mood ele-
vation symptoms considered in aggregate, as Perlis and 
associates found that residual mood elevation symptoms 
considered in aggregate (which can include irritability) 
predicted hastened depressive recurrence (Perlis et  al. 
2006).
Similarly, the relationship between current irritability 
and delayed depressive recovery indicated that irritability 
could have important longitudinal implications for acute 
bipolar depression. Although irritability does not cur-
rently count as one of the “non-overlapping” mood eleva-
tion symptoms towards depression with mixed features 
in adults (American Psychiatric Association 2013), pre-
vious studies have demonstrated that irritability is highly 
prevalent in, and is independently related to, mixed 
depression, which in turn can entail delayed recovery 
(Balázs et al. 2006; Benazzi and Akiskal 2003a, 2005; Pae 
et al. 2012; Perugi et al. 2015).
The relationships between current irritability and both 
depressive recurrence and depressive recovery are con-
sistent with the possibility of a particularly strong con-
nection between current irritability and longitudinal 
depressive burden. Shah and associates found that current 
irritability was the only assessed parameter to be signifi-
cantly associated with not only depressive recurrence but 
also depressive recovery (Shah et al. 2016 in review). Thus, 
although current irritability is robustly related to current 
anxiety (Yuen et al. 2016), the former may prove to be an 
even stronger predictor of delayed depressive recovery. 
Clearly, there is a need for additional study of the role of 
current irritability in longitudinal depressive severity.
Fig. 2 Current irritability associated with delayed depressive recovery 
in bipolar disorder. Two-year survival analysis of time to depressive 
recovery in depressed bipolar disorder patients indicated significantly 
delayed depressive recovery in patients with (N = 105, black line on 
right) vs. without (N = 48, gray line on left) current irritability (Log-
Rank p = 0.034). Current irritability was also significantly associated 
with delayed depressive recovery using Cox Proportional Hazard 
analysis (HR = 0.62; 95 % CI 0.39–0.97; p = 0.036). No other assessed 
parameter mediated delayed depressive recovery in patients with vs. 
without current irritability
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For example, further studies are needed to determine 
the direction of causality in the associations between cur-
rent irritability and hastened depressive recurrence and 
delayed depressive recovery. Treatment studies target-
ing irritability could assess its effect on bipolar course. 
Although this relationship remains to be examined in 
more detail, prior studies have indicated that adjunc-
tive quetiapine (Sokolski and Denson 2003) and adjunc-
tive gabapentin (Vieta et  al. 2000) can relieve not only 
depressive symptoms but also irritability. In addition, 
studies are needed to further characterize the contribu-
tions of lifetime history of anxiety disorder, prior year 
rapid cycling, and lifetime history of psychosis to the 
relationship between current irritability and depressive 
recurrence. Lifetime history of anxiety disorder may be 
of particular interest, as studies have demonstrated it to 
be robustly associated with both current irritability (Yuen 
et al. 2016) and depressive recurrence (Shah et al. 2016 in 
review).
Our study has the strengths of assessing relation-
ships between current irritability and not only hastened 
depressive recurrence but also delayed depressive recov-
ery, using validated instruments to assess diagnosis and 
longitudinal course, and having substantial numbers 
of both well-characterized recovered (N  =  105) and 
depressed (N =  153) BD patients. In addition, our cur-
rent irritability hastening depressive recurrence finding 
was not merely the result of subsequent mood elevation 
episodes leading to depression, as patients with sub-
sequent manic, hypomanic, and mixed episodes were 
censored.
Limitations of this study include the use of a sample 
referred to a suburban Northern California BD specialty 
clinic, limiting the generalizability of our findings in our 
relatively affluent, well educated but relatively under-
employed, predominantly female sample of BD patients 
with medical insurance. Moreover, our study was limited 
by: (1) the absence of use of a validated reliable irrita-
bility rating scale (e.g., the Buss-Durkee hostility inven-
tory); (2) the lack of determination of the mechanism(s) 
of loss of statistical significance (ranging from reduced 
reliability to reduced statistical power) when increas-
ing the threshold for current irritability from any to 4 
or 7 days; (3) the possibility that mild mixed depressive 
symptoms could have been detected as current irritabil-
ity and hence contributed to poorer prognosis—indeed 
in the entire sample, current irritability was associated 
with subsyndromal depressive symptoms (Yuen et  al. 
2016); and (4) the absence of use of a temperament 
assessment, limiting insight into character and pre-mor-
bid functioning. Additionally, our sample size, though 
substantial, had insufficient statistical power to be able 
to adequately assess relationships between current irri-
tability and times to mood elevation recurrence/recov-
ery. Furthermore, mood episode episode/recovered 
status duration prior to enrollment was not included in 
our analyses of mood episode recurrence and recovery. 
Another limitation is the open naturalistic treatment 
design, in which patients received diverse uncontrolled 
(albeit guideline-informed, measurement- and evidence-
based) therapies. Finally, we did not correct for multiple 
comparisons, which particularly limited interpretation 
of findings with p values between 0.05 and 0.01. How-
ever, this liberal statistical approach increased assay sen-
sitivity with respect to our ability to detect relationships 
between current irritability and depressive recurrence 
and recovery.
Nevertheless, we contend that our observation of asso-
ciations between current irritability and hastened depres-
sive recurrence as well as delayed depressive recovery 
suggests that irritability may be an important indica-
tor of longitudinal depressive burden in BD. Given the 
worse outcomes associated with bipolar depression and 
irritability, further examination of these relationships is 
warranted to better understand their mechanisms and 
clinical implications.
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